Oral Cancer News

HPV Vaccine Recommended for Boys aged 11 to 12 Years

Source: HemOncToday.com The CDC's Advisory Committee on Immunization Practices today approved routine recommendation in favor of administering the quadrivalent HPV vaccine for boys aged 11 to 12 years. Committee members decided that the vaccine (Gardasil, Merck) was safe, efficacious and cost-effective enough to warrant routine usage in this population. The recommendation issued in 2009 was permissive, meaning providers could give the vaccine to boys, but it was not routinely administered. This change would put the HPV vaccine into the regular vaccination schedule. The three-vaccination series can start as early as age 9 years. "The committee recommended that routine vaccination of males aged 11 or 12 years with three doses of quadrivalent vaccine be given to prevent HPV infection and HPV-related disease," Anne Schuchat, MD, director of the CDC's National Center for Immunization and Respiratory Diseases, said in a phone call with reporters. "Boys and young men 13 to 21 years of age who have not already received the vaccine should be vaccinated." Anne Schuchat, MD Insurance companies typically cover HPV vaccine in boys, but that is not necessarily the case for a permissive recommendation, according to Schuchat, who said a routine recommendation for a vaccine usually translates into coverage without co-pays. The committee voted 8-5 with one abstention in favor of recommending vaccination for young men up to age 21 years with permissive recommendation for men aged 22 to 26 years. The committee considered recommending vaccination up to age 26 years, which would have harmonized recommendations for men and women, [...]

Oral Cancer Foundation News Team - A2011-10-26T10:31:59-07:00October, 2011|Oral Cancer News|

CDC Committee Recommends Boys Receive HPV Vaccine

Source: CNN.com A federal government advisory committee voted Tuesday to recommend that boys and young men, from ages 11 to 21, be vaccinated against the human papilloma virus, commonly referred to as HPV. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices says the vaccine series can be started as early as age 9. Twelve members of the committee voted in favor of a recommendation that 11- and 12-year-old boys be vaccinated; one member abstained. A separate vote involving males age 13 to 21 was split. Eight voted for it; five voted against, and one abstained. The same recommendation said males age 22 through 26 may be vaccinated. HPV is the No. 1 sexually transmitted disease in the United States. At least 50% of sexually active people will get it at some point in their lives. Study: Males should get HPV vaccine too The HPV votes took place as part of the advisory committee's meeting in Atlanta, Georgia. The HPV vaccine is already recommended for females between the ages of 9 and 26 to reduce the risk of cervical cancer. The CDC recommends girls get the vaccine at age 11 or 12. The FDA approved the first HPV vaccine, Gardasil, back in 2006. The second vaccine, Cervarix, was approved in 2009. The vaccine is given in three doses. Gardasil also protects against most genital warts and has been shown to protect against anal, vaginal and vulvar cancers, all of which are associated with HPV, according to the [...]

Oral Cancer Foundation News Team - A2011-10-25T13:47:57-07:00October, 2011|Oral Cancer News|

New Fire Pepper Jelly Proceeds Help Benefit The Bruce Paltrow Oral Cancer Fund

Source: TheCelebrityCafe.com Jenkins Jellies was recently started by actress Hillary Danner, who was encouraged by a friend to invent a unique pepper jelly that has an extra kick of flavor. She brought in friends Maria Newman and Chef Jared Lavy to help out, resulting in the creation of the delicious, one-of-a-kind Hell Fire Pepper Jelly. The jelly is headlined by a perfect balance between a sweet taste of jelly and the hot kick you would expect from peppers. Hell Fire Pepper Jelly is unique in that it is versatile, with an infinite number of uses. Couple it with a variety of cheeses to give your sandwiches an extra kick. Use it as a glaze or marinade on streak, salmon, pork or chicken. It also makes for a great topper on burgers, hot dogs and meatloaf. The product is completely organic, with nothing artificial about it, which means you get the pure, unaltered natural blend of flavors. There are no preservatives, artificial flavors, high fructose corn syrup or food coloring. The ingredients strictly include a blend of seven fresh peppers, vinegar, organic sugar and pectin. Plus, the jelly is completely vegan friendly and gluten free. This delicious product has rightfully been recognized by celebrities like Chef Mario Batali and actors Ed Begley, Jr. and Gwyneth Paltrow. It is a delicious topper that will make the boring burger or steak pop with a unique flavor. It is available at Dean & DeLuca stores across the country, as well as online. Part of the profits go to Green [...]

Oral Cancer Foundation News Team - A2011-10-25T09:38:04-07:00October, 2011|Oral Cancer News|

Proper dental care for cancer patients: why it is important

Source: newcanaan.patch.com Author: Alan B. Sheiner DDS Common side effects from radiation therapy are not stressed enough in dental schools, but they can be managed and even prevented. A few weeks ago, I was contacted by a retired physician with whom I had not spoken for a number of years since he retired from practice to become a “gentleman farmer” in the country. While I was happy to hear from him, his news was not so good. He was calling because he had been treated for base of tongue cancer and his teeth were “coming apart”. His cancer treatment consisted of chemotherapy and radiation therapy. Unfortunately, he somehow “slipped through the cracks” and his oral cavity was now suffering from some of the side effects of the cancer therapy – fortunately he is currently cancer free. The oral cavity, one of the most complex and visible organ systems in the body, is invariably compromised as a result of treatment for head and neck cancer. Whether the malignancy is to be treated by surgery, radiation therapy, chemotherapy or a combination of these modalities, the function, if not also the form, of the oral cavity will be impacted. Aside from the obvious physical changes after cancer surgery to the head and neck region, there are issues which usually accompany radiation therapy to the head and neck region. There may be side effects from cancer therapy, some of which can be devastating, but preventable or manageable with proper precautions and care. The most [...]

Oral Cancer Foundation News Team - A2011-10-23T09:33:21-07:00October, 2011|Oral Cancer News|

The versatile application of cervicofacial and cervicothoracic rotation flaps in head and neck surgery

Source: thspace.com Author: staff The large defects resulting from head and neck tumour surgeries present a reconstructive challenge to surgeons. Although numerous methods can be used, they all have their own limitations. In this paper, we present our experience with cervicofacial and cervicothoracic rotation flaps to help expand the awareness and application of this useful system of flaps. Methods: Twenty-one consecutive patients who underwent repair of a variety of defects of the head and neck with cervicofacial or cervicothoracic flaps in our hospital from 2006 to 2009 were retrospectively analysed. Statistics pertaining to the patients'clinical factors were gathered. Results: Cheek neoplasms are the most common indication for cervicofacial and cervicothoracic rotation flaps, followed by parotid tumours. Among the 12 patients with medical comorbidities, the most common was hypertension. Defects ranging from 1.5 cm x 1.5 cm to 7 cm x 6 cm were reconstructed by cervicofacial flap, and defects from 3 cm x 2 cm to 16 cm x 7 cm were reconstructed by cervicothoracic flap. The two flaps also exhibited versatility in these reconstructions. When combined with the pectoralis major myocutaneous flap, the cervicothoracic flap could repair through-and-through cheek defects, and in combination with a temporalis myofacial flap, the cervicofacial flap was able to cover orbital defects. Additionally, 95% patients were satisfied with their resulting contour results. Conclusions: Cervicofacial and cervicothoracic flaps provide a technically simple, reliable, safe, efficient and cosmetic means to reconstruct defects of the head and neck. Authors: Fa-yu Liu, Zhong-fei Xu, Peng Li, Chang-fu Sun, [...]

Oral Cancer Foundation News Team - A2011-10-23T09:18:29-07:00October, 2011|Oral Cancer News|

Senate takes aim at tobacco in baseball

Source: chicagoist.com Author: Angie Wiatrowsk As the Rangers and Cardinals play in the World Series, the U.S. Senate is pushing for something else. As if they have nothing better to do. Four United States Senators, including Dick Durbin of Illinois, and health officials from St. Louis and Arlington, TX. made pleas in separate letters in hopes of banning chewing tobacco at baseball games and on camera. They want to stress not only the harmful effects on the players, but the image they're sending to children who watch them. St. Louis public health authority Pamela Walker said in her letter, "Younger people believe smokeless tobacco is a safer alternative to cigarettes, and when they see people they idolize do it that reinforces that belief. Not only that, it makes dipping look cool." Baseball players dipping is no news, it's been affecting kids for years whether we tend to ignore it or not. Shoot, the term "bullpen" came to existence when Blackwell Tobacco Company released Bull Durham brand tobacco in 1860. After all, who as a kid growing up playing ball didn't have their share of Big League Chew? That's right, before you hit the field, pull out that stringy wad of "groundball grape" and stick it in your cheek like the guys on TV. It was an alternative to chewing tobacco that was very well marketed to kids. It was created by Portland Mavericks' pitcher Rob Nelson and New York Yankees' Jim Bouton. The two were sitting in the bullpen and [...]

Oral Cancer Foundation News Team - A2011-10-23T09:13:24-07:00October, 2011|Oral Cancer News|

Ethanol Promotes Chemically Induced Oral Cancer in Mice through Activation of the 5-Lipoxygenase Pathway of Arachidonic Acid Metabolism

Source: Cancer Prevention Research Abstract Alcohol drinking is a known risk factor for oral cancer in humans. However, previous animal studies on the promoting effect of ethanol on oral carcinogenesis were inconclusive. It is necessary to develop an animal model with which the molecular mechanism of ethanol-related oral carcinogenesis may be elucidated to develop effective prevention strategies. In this study, mice were first treated with 4-nitroquinoline-1-oxide (4NQO, 100 μg/mL in drinking water) for 8 weeks and then given water or ethanol (8%) as the sole drink for another 16 weeks. During the experiment, 8% ethanol was well tolerated by mice. The incidence of squamous cell carcinoma (SCC) increased from 20% (8/41) to 43% (17/40; P < 0.05). Expression of 5-lipoxygenase (5-Lox) and cyclooxygenase 2 (Cox-2) was increased in dysplasia and SCC of 4NQO-treated tongues and further enhanced by ethanol. Using this mouse model, we further showed that fewer cancers were induced in Alox5−/− mice, as were cell proliferation, inflammation, and angiogenesis in the tongue, as compared with Alox5+/+ mice. Interestingly, Cox-2 expression was induced by ethanol in knockout mice, whereas 5-Lox and leukotriene A4 hydrolase (LTA4H) expression and leukotriene B4 (LTB4) biosynthesis were dramatically reduced. Moreover, ethanol enhanced expression and nuclear localization of 5-Lox and stimulated LTB4 biosynthesis in human tongue SCC cells (SCC-15 and SCC-4) in vitro. In conclusion, this study clearly showed that ethanol promoted 4NQO-induced oral carcinogenesis, at least in part, through further activation of the 5-Lox pathway of arachidonic acid metabolism. This news story was resourced [...]

Oral Cancer Foundation News Team - A2011-10-19T15:36:04-07:00October, 2011|Oral Cancer News|

Thyroid Dysfunction from Antineoplastic Agents

Source: Journal of the National Cancer Institute Abstract Unlike cytotoxic agents that indiscriminately affect rapidly dividing cells, newer antineoplastic agents such as targeted therapies and immunotherapies are associated with thyroid dysfunction. These include tyrosine kinase inhibitors, bexarotene, radioiodine-based cancer therapies, denileukin diftitox, alemtuzumab, interferon-α, interleukin-2, ipilimumab, tremelimumab, thalidomide, and lenalidomide. Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid-stimulating hormone secretion and thyroid hormone metabolism have also been described. Most agents cause thyroid dysfunction in 20%–50% of patients, although some have even higher rates. Despite this, physicians may overlook drug-induced thyroid dysfunction because of the complexity of the clinical picture in the cancer patient. Symptoms of hypothyroidism, such as fatigue, weakness, depression, memory loss, cold intolerance, and cardiovascular effects, may be incorrectly attributed to the primary disease or to the antineoplastic agent. Underdiagnosis of thyroid dysfunction can have important consequences for cancer patient management. At a minimum, the symptoms will adversely affect the patient’s quality of life. Alternatively, such symptoms can lead to dose reductions of potentially life-saving therapies. Hypothyroidism can also alter the kinetics and clearance of medications, which may lead to undesirable side effects. Thyrotoxicosis can be mistaken for sepsis or a nonendocrinologic drug side effect. In some patients, thyroid disease may indicate a higher likelihood of tumor response to the agent. Both hypothyroidism and thyrotoxicosis are easily diagnosed with inexpensive and specific tests. In many patients, particularly those with hypothyroidism, the treatment is straightforward. We therefore recommend routine testing for thyroid abnormalities [...]

Oral Cancer Foundation News Team - A2011-10-19T15:29:24-07:00October, 2011|Oral Cancer News|

New Guidelines for Reirradiation of Head and Neck Cancer

Source: Medscape News Today When head and neck cancer recurs and surgery is not an option, reirradiation provides the only potentially curative option. However, because the tumor often recurs in the same place or very close to tissue that has already been irradiated, this treatment approach represents a "significant challenge." For this reason, it should be handled at a tertiary-care center, according to a new guideline issued by the American College of Radiology. Specifically, it stipulates that the tertiary center should have a head and neck oncology team that is equipped with the resources and the experience to manage the complexities and toxicities of retreatment. In the guideline, published in the International Journal of Radiation Oncology, Biology and Physics, a panel of experts outline appropriateness criteria for various clinical scenarios that arise with such patients. It provides a consensus on how patients should be managed. "This is an important document because it is the first set of guidelines for the potentially curative treatment of patients who have regrowth of head and neck tumors. It provides a consensus on how patients should be managed," coauthor Madhur Kumar Garg, MD, said in a statement. Dr. Garg is from the Department of Radiation Oncology at Montefiore Medical Center, in the Bronx, New York, where about a dozen reirradiation procedures are performed annually. Commitment to Retreatment Retreatment is justified because clinical trial results have shown that local treatment improves overall survival, the panel of experts notes. However, they emphasize that, before a commitment to [...]

Oral Cancer Foundation News Team - A2011-10-18T10:35:08-07:00October, 2011|Oral Cancer News|

New Therapies and Prognostic Techniques Highlighted in Head and Neck Cancer

The Asco Post D. Neil Hayes, MD, MPH, of the University of North Carolina at Chapel Hill, described efforts to position the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) in head and neck cancer treatment. Surprisingly negative results came from the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940), which showed no benefit to adding cetuximab to the radiation/cisplatin platform for front-line therapy of advanced head and neck squamous cell carcinoma.1 At 2 years, progression-free survival was approximately 64% in both arms; overall survival was 79.7% with chemoradiation (P = .68) and 82.6% with the addition of cetuximab (P = .17). Rates of locoregional relapse and distant metastases were also similar. Cetuximab increased grade 3/4 mucositis (43% vs 33%;P < .004), in-field skin toxicity (25% vs 15%;P < .001), and out-of-field skin reactions (19% vs 1%;P < .001), but toxicity beyond 90 days was similar between the arms. "RTOG 0522 was the study of the year in head and neck cancer. Unfortunately, it was flat-out negative," Dr. Hayes noted. No differential effect emerged by p16 (HPV status). "While 70% of patients had oropharynx tumors (suggesting HPV positivity), tissue collection was lacking in half the patients. Our ability to make inferences with this amount of missing data is very limited," Dr. Hayes said. Even as a negative study, RTOG 0522 is practice-changing. "Many physicians have been treating with this regimen, assuming this study would be positive," he said. "But we now have no data to support this." Cetuximab Equivalent [...]

Oral Cancer Foundation News Team - A2011-10-18T09:58:29-07:00October, 2011|Oral Cancer News|